EXTON, Pa., March 22, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced data presented in two poster presentations relating to Cinryze® (C1 esterase inhibitor [human]) at the 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, March 18 through 22, in San Francisco, CA.
Cinryze is the first and only U.S. FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease. Cinryze is currently available only in the United States, and is not approved in the U.S. to treat acute angioedema attacks, for children with HAE, or for pre-procedure administration.
"As leaders in hereditary angioedema medical education, we continue to expand the body of data available on Cinryze usage," commented David Mariano, PharmD, ViroPharma's director of medical communications. "Our goal is to leverage educational initiatives to reinforce the understanding and awareness of HAE and its management for physicians and other healthcare professionals who may care for patients suffering from HAE."
AAAAI Poster Presentations
In a poster entitled, 'Pre-procedural Administration of Nanofiltered C1 Esterase Inhibitor (Human) (Cinryze®) for the Prevention of Hereditary Angioedema (HAE) Attacks after Medical, Dental, or Surgical Procedures,' Dr. William Lumry, M.D., of the University of Texas Southwestern Medical School in Dallas, Texas discussed the potential for Cinryze to prevent attacks of HAE that are triggered by trauma such as dental work, elective medical procedures and surgery. Data compiled from all completed studies with Cinryze were presented on the experience of 41 subjects who received Cinryze prior to 91 procedures. Cinryze 1000U